Blood Product Manufacturers Begin New Round Of Fund-Raising
This article was originally published in PharmAsia News
Executive Summary
Following the footsteps of Hualan Biological Engineering, Beijing Tiantan Biological Products and Beisheng Pharma, Shanghai RAAS Blood Products will be the fourth blood product company listing on the China stock market. It plans to use the fund to extend its production line and R&D processes. Meanwhile, Hualan Biological Engineering has issued new shares to scale up its manufacturing capacity. Some analysts point out that the recent lethal immunoglobulin incident may result in more stringent supervision and approval of blood product manufacturing and expansion. However, most observers believe that qualified large companies' plans will not be restricted due to the limited supply of blood products; rather, insufficient blood plasma source will directly impact their performance. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.